In a report released on February 1, Jack Allen from Robert W. Baird maintained a Buy rating on Instil Bio (TIL – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $0.89.
According to TipRanks, Allen is an analyst with an average return of -10.2% and a 40.58% success rate. Allen covers the Healthcare sector, focusing on stocks such as Vor Biopharma, Frequency Therapeutics, and Instil Bio.
Instil Bio has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See the top stocks recommended by analysts >>
TIL market cap is currently $105.6M and has a P/E ratio of -0.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.
Read More on TIL:
- Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
- Instil Bio extends cash runway with consolidation of R&D operations
- Instil Bio sees cash runway into 2025
- Instil Bio resumes clinical trial of ITIL-306 in lung, ovarian, renal cancer
- Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
